immunic, inc., a clinical-stage biopharmaceutical company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases, including relapsing-remitting multiple sclerosis, ulcerative colitis, crohn's disease, and psoriasis. its lead development program is imu-838, a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme dihydroorotate dehydrogenase, which is in phase 2 clinical development for treatment of ulcerative colitis and relapsing-remitting multiple sclerosis, as well as in phase 2 trial to treat crohn's disease. the company is also developing imu-935, an inverse agonist of rorgt; and imu-856 for the restoration of the intestinal barrier function in patients suffering from diseases, such as inflammatory bowel disease, irritable bowel syndrome with diarrhea, immune checkpoint inhibitor induced colitis, and other intestinal barrier function diseases. immu
Company profile
Ticker
IMUX
Exchange
Website
CEO
Daniel Vitt
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
VITAL THERAPIES INC
SEC CIK
Corporate docs
Subsidiaries
Immunic AG ...
IMUX stock data
Latest filings (excl ownership)
8-K
Amendments to Articles of Incorporation or Bylaws
8 Mar 24
S-3/A
Shelf registration (amended)
1 Mar 24
10-K
2023 FY
Annual report
22 Feb 24
8-K
Immunic, Inc. Reports Year End 2023 Financial Results and Provides Corporate Update
22 Feb 24
S-3
Shelf registration
13 Feb 24
DEF 14A
Definitive proxy
5 Feb 24
PRE 14A
Preliminary proxy
24 Jan 24
D
Exempt offering of security
19 Jan 24
8-K
Immunic, Inc. Announces Private Placement of up to $240 Million
5 Jan 24
8-K
Departure of Directors or Certain Officers
21 Dec 23
Transcripts
IMUX
Earnings call transcript
2023 Q4
22 Feb 24
IMUX
Earnings call transcript
2023 Q3
14 Nov 23
IMUX
Earnings call transcript
2023 Q2
3 Aug 23
IMUX
Earnings call transcript
2023 Q1
11 May 23
IMUX
Earnings call transcript
2022 Q4
23 Feb 23
IMUX
Earnings call transcript
2022 Q3
3 Nov 22
IMUX
Earnings call transcript
2022 Q2
6 Aug 22
IMUX
Earnings call transcript
2022 Q1
10 May 22
IMUX
Earnings call transcript
2021 Q4
24 Feb 22
IMUX
Earnings call transcript
2021 Q3
6 Nov 21
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 59.69 mm | 59.69 mm | 59.69 mm | 59.69 mm | 59.69 mm | 59.69 mm |
Cash burn (monthly) | 5.87 mm | 1.09 mm | 7.86 mm | 11.10 mm | 5.77 mm | 5.99 mm |
Cash used (since last report) | 39.14 mm | 7.27 mm | 52.41 mm | 74.02 mm | 38.49 mm | 39.97 mm |
Cash remaining | 20.55 mm | 52.42 mm | 7.28 mm | -14.33 mm | 21.20 mm | 19.72 mm |
Runway (months of cash) | 3.5 | 48.1 | 0.9 | -1.3 | 3.7 | 3.3 |
Institutional ownership, Q2 2023
27.8% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 68 |
Opened positions | 12 |
Closed positions | 8 |
Increased positions | 21 |
Reduced positions | 12 |
13F shares | Current |
---|---|
Total value | 48.52 bn |
Total shares | 25.04 mm |
Total puts | 144.50 k |
Total calls | 86.30 k |
Total put/call ratio | 1.7 |
Largest owners | Shares | Value |
---|---|---|
RTW Investments | 4.29 mm | $10.78 bn |
LSP V Cooperatieve U.A. | 2.16 mm | $4.26 mm |
Roi Verwaltungs GMBH | 1.97 mm | $2.86 mm |
Omega Fund Management | 1.79 mm | $4.49 bn |
Gratus Capital | 1.68 mm | $4.21 bn |
Vanguard | 1.68 mm | $4.21 bn |
BVF | 1.15 mm | $2.89 bn |
Millennium Management | 945.80 k | $2.37 bn |
Ubs Oconnor | 791.69 k | $1.99 bn |
Artal International S.C.A. | 700.00 k | $10.70 mm |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
4 Mar 24 | Neermann Joerg | Stock Option Common Stock | Grant | Acquire A | No | No | 1.72 | 64,959 | 111.73 k | 64,959 |
4 Mar 24 | Neermann Joerg | Stock Option Common Stock | Sale back to company | Dispose D | No | No | 3.4 | 10,000 | 34.00 k | 0 |
4 Mar 24 | Neermann Joerg | Stock Option Common Stock | Sale back to company | Dispose D | No | No | 14.77 | 10,000 | 147.70 k | 0 |
4 Mar 24 | Neermann Joerg | Stock Option Common Stock | Sale back to company | Dispose D | No | No | 12.3 | 15,000 | 184.50 k | 0 |
4 Mar 24 | Neermann Joerg | Stock Option Common Stock | Sale back to company | Dispose D | No | No | 13.63 | 29,959 | 408.34 k | 0 |
4 Mar 24 | Monika Maria Toernsen | Stock Option Common Stock | Grant | Acquire A | No | No | 1.72 | 30,000 | 51.60 k | 30,000 |
4 Mar 24 | Monika Maria Toernsen | Stock Option Common Stock | Sale back to company | Dispose D | No | No | 4.3 | 30,000 | 129.00 k | 0 |
4 Mar 24 | Vitt Daniel | Stock Option Common Stock | Grant | Acquire A | No | No | 1.72 | 485,000 | 834.20 k | 485,000 |
4 Mar 24 | Vitt Daniel | Stock Option Common Stock | Sale back to company | Dispose D | No | No | 3.4 | 10,000 | 34.00 k | 0 |
4 Mar 24 | Vitt Daniel | Stock Option Common Stock | Sale back to company | Dispose D | No | No | 10.73 | 215,000 | 2.31 mm | 0 |
News
Brookline Capital Initiates Coverage On Immunic with Buy Rating, Announces Price Target of $10
5 Apr 24
Immunic And 2 Other Stocks Under $2 Insiders Are Buying
29 Feb 24
Immunic Q4 EPS $(0.48) Beats $(0.51) Estimate, Cash And Equivalents As Of December 31, 2023 Were $46.7M
22 Feb 24
Earnings Scheduled For February 22, 2024
22 Feb 24
Immunic's Earnings Outlook
21 Feb 24
Press releases
Immunic to Host MS R&D Day and Participate in Investor Conferences in April
4 Apr 24
Immunic to Host MS R&D Day and Participate in Investor Conferences in April
4 Apr 24
Immunic CMO discusses complexities of multiple sclerosis to mark MS Awareness Month
21 Mar 24
Immunic secures key patent, boosting MS drug exclusivity and global IP strategy
21 Mar 24
Immunic to reveal promising MS treatment data in two poster presentations at ACTRIMS Forum 2024
8 Mar 24